(Q79711344)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Diffuse large B-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

Jonathan W Friedberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Richard I Fisher

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

Hematology / Oncology Clinics of North America

25 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

941-52, ix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

25 December 2019

cites work

1 reference

12 December 2020

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

12 December 2020

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

12 December 2020

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

1 reference

12 December 2020

The epidemiology of non-Hodgkin's lymphoma

1 reference

12 December 2020

Time trends of non-Hodgkin's lymphoma: are they real? What do they mean?

1 reference

12 December 2020

Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence

1 reference

12 December 2020

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

12 December 2020

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

12 December 2020

Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b

1 reference

12 December 2020

Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications

1 reference

12 December 2020

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

12 December 2020

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

1 reference

12 December 2020

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

12 December 2020

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

1 reference

12 December 2020

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

12 December 2020

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications

1 reference

12 December 2020

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

1 reference

12 December 2020

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation

1 reference

12 December 2020

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

12 December 2020

The role of environmental factors in the etiology of lymphoma

1 reference

12 December 2020

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

1 reference

12 December 2020

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

12 December 2020

Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.

1 reference

12 December 2020

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group

1 reference

12 December 2020

Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma

1 reference

12 December 2020

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

1 reference

12 December 2020

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

12 December 2020

The role of molecular studies in lymphoma diagnosis: a review.

1 reference

12 December 2020

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

12 December 2020

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

1 reference

12 December 2020

10.1016/J.HOC.2008.07.002

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18954744%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference